The Global Medical Alpha Radionuclide Market was valued at USD 3.28 Billion in 2023 and is projected to reach USD 8.52 Billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 14.6% during the forecast period (2023-2030). This rapid growth is fueled by increasing adoption of targeted alpha therapy (TAT) in oncology, rising cancer prevalence, and advancements in radiopharmaceutical production techniques.
As precision medicine transforms cancer treatment, the focus intensifies on companies developing alpha-emitter isotopes and innovative drug conjugates. In this analysis, we profile the Top 10 Companies in the Medical Alpha Radionuclide Industry—nuclear technology pioneers and biopharma innovators shaping the future of radiopharmaceutical therapeutics.
🔟 1. Oak Ridge National Laboratory (ORNL)
Headquarters: Oak Ridge, Tennessee, USA
Key Offering: Actinium-225, Thorium-229
ORNL leads in alpha radionuclide research through its DOE-funded Isotope Program. The laboratory develops novel production methods for Ac-225, a prized isotope for targeted alpha therapy, using its High Flux Isotope Reactor (HFIR).
Research Breakthroughs:
-
Pioneered accelerator-based production of Ac-225
-
Developed Th-229 generator systems for sustainable supply
-
Collaborates with 30+ biotech firms on therapeutic applications
Download FREE Sample Report: Medical Alpha Radionuclide Market – View in Detailed Research Report
9️⃣ 2. Tri-Lab Research Team